Sangamo BioSciences Inc. ($SGMO) stock snapped its negative streak as it jumped to $3.35 in its Friday trading session. The stock eventually closed at $3.20, 18.52% higher. The company presented preclinical and manufacturing data that support SB-525, its gene therapy program for hemophilia A, at the 58th Annual Meeting of the American Society of Hematology (ASH) held in San Diego, CA, from December 3-6, 2016.
Sangamo reported that the data showed the company’s ability to perform beyond its ZFP platform. It also demonstrated its R&D and technical operations teams’ ability to rapidly develop a program from research data.